Exelixis, Inc.: Zanzalintinib Clinical Progression and Market Development Strategy!

Exelixis reported its first quarter 2024 financial results, underlining continued progress in its business across several fronts. The company, known for its cabozantinib franchise, saw a modest growth in revenues, driven by sustained demand and expansion in the U.S. and global markets. Additionally, Exelixis advanced in its pipeline development and corporate developments, maintaining a robust focus on enhancing standard of cancer care and providing value to shareholders.